SFC840-03-03 LRRK2 WT/R1441C H3
STBCi026-A-3
General
Cell Line |
|
hPSCreg name | STBCi026-A-3 |
Cite as: | STBCi026-A-3 (RRID:CVCL_A9A0) |
Alternative name(s) |
SFC840-03-03 LRRK2 WT/R1441C H3
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
STBCi026-A-1 (SFC840-03-03 LRRK2-/-D10) STBCi026-A-2 (SFC840-03-03 LRRK2-/-C11) STBCi004-B-1 (SFC832-03-06 LRRK2WT/WT C47) Donor's gene variants: LRRK2 Donor diseases: Parkinson disease STBCi026-A (SFC840-03-03) STBCi026-A-4 (SFC840-03-03-PITX3-GFP) STBCi026-B (SFC840-03-01) STBCi026-C (SFC840-03-05) STBCi026-D (SFC840-03-06) EDi001-A-2 (AST23-1KO-3, AST22-1KO-3, AST-23_SCAKO Clone 3, AST-22_SNCAKO Clone 3) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A-3 (AST23_SNCAKO Clone 1, AST22-1KO-1, AST23-1KO-1, AST22_SNCAKO Clone 1) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A-4 (AST22-2KO-6, AST23_SNCAKO Clone 6, AST22_SNCAKO Clone 6, AST23-2KO-6) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease GIBHi002-A-1 (C5-PARK2-KO) BIONi037-A-2 (BIONi037-A ApoE2/2 #M10-7) BIONi037-A-3 (BIONi037-A ApoE3/4 #P10-22) BIONi037-A-4 (BIONi037-A ApoE4/4 #I10-53) BIONi037-A-1 (16423 ApoE KO) WAe009-A-1P (IsoHD-30Q-NGN2) WAe009-A-1Q (IsoHD-65Q-NGN2) WAe009-A-1R (IsoHD-81Q-NGN2) SIGi001-A-13 (iPSC0028 – MonoAllelic MAPT_Ex10+16T/Clone 1D01-11) |
Last update | 14th May 2022 |
User feedback | |
Provider |
|
Generator | StemBANCC (STBC) |
Distributors | |
External Databases |
|
BioSamples | SAMEA5859481 |
Cellosaurus | CVCL_A9A0 |
Wikidata | Q102114947 |
General Information |
|
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Subclone of |
Donor Information
General Donor Information |
|
Sex | female |
Phenotype and Disease related information (Donor) |
|
Diseases | No disease was diagnosed.
|
Donor Relations |
|
Other cell lines of this donor | |
External Databases (Donor) |
|
BioSamples | SAMEA104493661 |
Ethics
Also have a look at the ethics information for the parental line
STBCi026-A
.
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
The source cell information can be found in the parental cell line
STBCi026-A.
|
|
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Sendai virus |
Is reprogramming vector detectable? |
No |
Methods used |
PCR
|
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzyme-free cell dissociation
EDTA
|
Medium |
mTeSR™ 1
|
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
NANOG |
Yes |
|
||||
TRA 1-60 |
Yes |
|
Microbiology / Virus Screening |
|
HIV 1 | Negative |
HIV 2 | Negative |
Hepatitis B | Negative |
Hepatitis C | Negative |
Mycoplasma | Negative |
Certificate of Analysis |
|
Is there a certificate of analysis available? |
Yes
Passage:
|
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
No gross karyotypic abnormalities observed, 6 small indels as in parent line
Passage number: 31
Karyotyping method:
Molecular karyotyping by SNP array
http:// |
Other Genotyping (Cell Line) |
Genetic Modification
Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.